GLOW

What is GLOW?

GLOW is a supplier designation for a pre-blended multi-peptide research vial, not a single chemical entity. The GLOW 70mg vial contains BPC-157 10mg (pentadecapeptide GEPPPGKPADDAGLV, C₆₂H₉₈N₁₆O₂₂, 1419.53 g/mol, CAS 137525-51-0), TB-500 10mg (synthetic thymosin beta 4, 43 residues N-terminally acetylated, C₂₁₂H₃₅₀N₅₆O₇₈S, 4963.4 g/mol, CAS 77591-33-4) and GHK-Cu 50mg (glycyl-L-histidyl-L-lysine copper(II) complex, C₁₄H₂₄CuN₆O₄, 403.9 g/mol, CAS 89030-95-5), co-lyophilised in a single container. Because the components are co-lyophilised, one reconstitution step puts all three into solution at a fixed ratio, and they cannot subsequently be separated or independently varied. The blend itself has not been studied as a combination; the published evidence is three separate single-compound literatures. Supplied as lyophilised powder for in-vitro research use only, not a licensed medicine, and no therapeutic, cosmetic or appearance claim is made or implied.

GLOW vs KLOW vs Individual Vials

The three formats differ in composition and in experimental flexibility, not in quality. GLOW is 70mg total: BPC-157 10mg, TB-500 10mg, GHK-Cu 50mg. KLOW is the same three components at the same masses plus KPV 10mg, giving 80mg total, and adds a mechanistically distinct compound whose literature centres on PepT1-mediated uptake and NF-κB signalling in epithelial and colitis models rather than on angiogenesis, actin dynamics or copper transport. Individual BPC-157, TB-500 and GHK-Cu vials cost more in handling steps but are the only format that permits a single-compound control arm, an independent concentration per compound, or attribution of an observed effect to a specific molecule. One further note on the blend formats: because GHK-Cu is 403.9 g/mol against 1419.53 for BPC-157 and 4963.4 for thymosin beta 4, the 50:10:10 mass split is nothing like a 5:1:1 molar ratio, so molar arithmetic must be done component by component. Note also the supply-format difference across the market: GLOW and KLOW are sold by some suppliers as five- and six-vial kits, whereas the material here is a single pre-blended vial taking one reconstitution.

GLOW Research Applications

Each component of the GLOW blend has its own preclinical and in-vitro literature, and the blend has none of its own. BPC-157 appears in in-vitro and animal work on angiogenesis and endothelial tube formation, focal adhesion signalling, gastrointestinal mucosal integrity and nitric oxide pathway modulation; Hsieh et al. (J Mol Med, 2017) reported VEGFR2 upregulation and receptor internalisation in human umbilical vein endothelial cells, and Chang et al. (J Appl Physiol, 2011) reported FAK and paxillin phosphorylation with increased outgrowth and migration in cultured rat tendon fibroblasts. A 2025 review by McGuire and colleagues in Current Reviews in Musculoskeletal Medicine found no adequately powered randomised controlled trial. TB-500 is synthetic thymosin beta 4, the principal G-actin sequestering molecule in eukaryotic cells; Philp et al. (FASEB J, 2003) reported that the LKKTETQ actin-binding motif at residues 17 to 23 is sufficient to promote endothelial cell migration in aortic ring and chorioallantoic assays, and Bock-Marquette et al. (Nature, 2004) reported integrin-linked kinase and Akt activation in mouse cardiac models. GHK-Cu is studied as a copper delivery ligand and as a matrikine, the GHK motif occurring within the alpha-2(I) chain of type I collagen; Pickart et al. (Nature, 1980) reported facilitated copper uptake into cultured cells, Siméon et al. (Life Sci, 2000) reported upregulated matrix metalloproteinase-2 alongside its tissue inhibitors in fibroblast culture, and Maquart et al. (J Clin Invest, 1993) reported connective tissue accumulation endpoints in a rat diffusion-chamber model. Because these findings come from different systems at different scales, they cannot be summed into a prediction about the blend, and any design attributing an effect to a single component requires the individual vials.

Reconstitution Guide

Allow vials to reach room temperature, then sterilise the rubber stopper of both the peptide vial and the bacteriostatic water vial with an alcohol swab. Slowly draw your bacteriostatic water into a sterile insulin syringe, then inject it gently down the inner glass wall of the peptide vial, never directly onto the lyophilised powder. Once added, gently swirl the vial in a slow circular motion until fully dissolved. Never shake or vortex. The solution should be clear and colourless. Label the vial with the reconstitution date and store immediately. Two blend-specific points apply. Never shake or vortex, the 43-residue thymosin beta 4 component is shear sensitive and agitation reduces recovery of intact peptide. And the reconstituted solution will not be colourless: expect a blue to blue-violet tint from the d-d transition of the Cu(II) centre in the GHK-Cu component, which is expected and is the standard bench indicator that the copper complex is intact. A colourless or green-tinged solution indicates the complex has been disrupted rather than simply diluted, and visible absorption around 500 to 600 nm is the usual check. Reconstitute away from direct light and use glass or high-grade polypropylene labware, avoiding prolonged contact with stainless steel or other chelating surfaces that can strip Cu(II) from the tripeptide.

See our full peptide reconstitution guide and reconstitution calculator for step-by-step protocol.

Storage Instructions

Lyophilised vials should be stored at -20°C, protected from light and moisture, and remain stable for up to 24 months. Once reconstituted with bacteriostatic water, store the solution at 2-8°C (standard refrigerator) and use within approximately 3 months. For storage beyond that, prepare single-use aliquots at -20°C, where reconstituted peptide remains stable for up to 6 months. Avoid repeated freeze-thaw cycles and always handle under sterile laboratory conditions. Light protection matters more for GLOW than for a single-peptide vial, because a copper(II) peptide complex is photolabile and the whole blend must be handled to the standard of its most fragile component. Keep lyophilised vials and reconstituted solution shielded from UV and fluorescent light and use amber or foil-wrapped vessels for aliquots. Freeze-thaw cycling can disrupt the copper coordination sphere as well as degrade the peptide backbones, so single-use aliquots are preferable to repeatedly accessing one stock.

Frequently Asked Questions

Research References

• Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation (Hsieh et al., J Mol Med, 2017)
• The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival and cell migration (Chang et al., J Appl Physiol, 2011)
• The actin binding site on thymosin beta4 promotes angiogenesis (Philp et al., FASEB J, 2003)
• Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair (Bock-Marquette et al., Nature, 2004)
• Growth-modulating plasma tripeptide GHK may function by facilitating copper uptake into cells (Pickart et al., Nature, 1980)
• The tripeptide-copper complex GHK-Cu stimulates matrix metalloproteinase-2 expression by fibroblast cultures (Siméon et al., Life Sci, 2000)

Related Research Compounds

• → KLOW 80mg
• → BPC-157 5mg
• → TB-500 5mg
• → GHK-Cu 50mg
• → BPC-157 + TB-500 5+5mg
• → Bacteriostatic Water 10ml